For those looking to apply to the Diamond Light Source/University of Reading studentship, please click on the link below and follow the links through to the University of Reading RISIS application system. You should apply for a PhD in Pharmacy, quoting the reference GS18-026.
Just out in Bioscience Reports, Claudia from the group has published a paper suggesting that chronic inhibition of LRRK2 can alter phosphorylation of ULK1 – an important regulator of macroautophagy.
Read all about it here:
On Friday I was privileged to act as judge for the Maiden Erlegh school science fair, where students from across the year groups had worked on topics as wide ranging as “the science of dragons” to “what is it like to be colour blind?”. I was really impressed by the standard of the presentations, the only shame was that I had to choose winners for each key stage – the students made my job very difficult!
The deadline for our EPSRC studentship on macroautophagy has been extended to the end of the month. See link below for details…
The deadline for the four year PhD in collaboration with Diamond Light Source has been extended to the end of the month! The project will use state of the art structural biology approaches to shine a light on the biology of the ROCO proteins, such as LRRK2, and help us understand how this protein is involved in Parkinson’s disease.
See link below for details.
Just out in Proteomics, James Tomkins and Claudia Manzoni from the group have published a fascinating study on the comparative interactomes of the ROCO proteins (including LRRK2). This study sheds light on some of the common pathways and different functions of these proteins. The abstract is now online, and I will update once the open access paper is available.
Alice Price, who just completed a Masters by research in the lab, has a new review out on the LRRK2 signaling system in Cell and Tissue Research. This looks at LRRK2 from a systems biology perspective, putting together a framework for understanding and interpreting how mutations in LRRK2 perturbs the biology of the human brain. Read all about it here:
I’ve just written a short piece for the conversation on the use of antisense oligonucleotide approaches to target neurodegeneration – following on from recent media reports about a phase 1 clinical trial in Huntington’s disease. A really interesting area of research, and one that has the potential to be relevant for a wide range of diseases.
Read all about it here: https://theconversation.com/antisense-therapy-a-promising-new-way-to-treat-neurological-disease-89006
Just out in Frontiers in Molecular Neuroscience, a paper from Laura Civiero and the Greggio group (including Susanna, who has been in the lab here in Reading for the last 9 months). This is a really interesting studying of the kinase PAK6, which Laura and Elisa previously linked to LRRK2, demonstrating that it can phosphorylate 14-3-3gamma – read all about it below:
We’ve been very fortunate to have two great visiting PhD students – Susanna Cogo from Elisa Greggio’s group at the University of Padova, and Clara Ruz from Raquel Duran’s group at the University of Granada. Both have been working on LRRK2 in some shape or form, and have done some great work – but are now heading back to Italy and Spain respectively. This is the lab saying farewell at the Prince Alfred pub last week – one last taste of British cuisine!